Transchem Limited has completed the acquisition of 100% equity in Greshma Shares and Stocks Limited (GSSL) for a total consideration of ₹25.91 crore. The deal, finalized through a Share Purchase Agreement executed on August 17, 2026, marks the chemical manufacturer’s strategic entry into the financial services sector.

The transaction involved the purchase of 1,55,16,000 equity shares at a price of ₹16.70 per share. Upon completion, GSSL became a wholly-owned subsidiary of Transchem. The move is designed to leverage GSSL’s existing platform in stock broking and depository services to broaden Transchem’s revenue base and create synergies in future expansion within the financial domain.

Acquisition Details

The deal was structured as an arm’s length transaction with no related-party involvement. Transchem confirmed that its promoters, promoter group, and group companies held no prior direct or indirect interest in GSSL. The consideration was discharged entirely in cash.

Regulatory Approvals

Transchem secured all necessary regulatory clearances for the change in control of GSSL, which is registered with the Securities and Exchange Board of India (SEBI) as a stock broker and Central Depository Services (India) Limited (CDSL) depository participant. The approvals were obtained prior to the execution of the SPA:

• NSE Clearing Limited: NOC dated January 5, 2026
• National Stock Exchange of India Limited: NOC dated March 16, 2026
• Indian Clearing Corporation Limited: Approval dated March 24, 2026
• BSE Limited: Prior approval dated April 23, 2026
• CDSL: Prior approval dated May 25, 2026
• SEBI: Final approval dated June 19, 2026

What the Numbers Show

GSSL’s financial performance shows a contraction in turnover over the last fiscal year. As on March 31, 2026, the entity reported a net worth of ₹21.32 crore. Its annual turnover fell to ₹5.98 crore in FY26, compared to ₹11.32 crore in FY25 and ₹9.47 crore in FY24. This decline suggests that Transchem’s valuation of ₹25.91 crore implies a premium paid for regulatory licenses and market access rather than current revenue multiples.

GSSL operates as a member of NSE (Cash Market, Futures & Options) and BSE (Cash Market). Its services include trading in equities and derivatives, distribution of IPOs and mutual funds, exchange-traded funds, and packaged financial solutions via terminal-based and online platforms.

Transchem Limited reported a net profit of ₹342.11 lakh for the quarter ended June 30, 2026 (Q1FY26), marking a significant 244% year-on-year increase from ₹99.33 lakh in Q1FY25. The chemical manufacturer’s total income surged to ₹511.36 lakh, up from ₹163.58 lakh in the same period last year, driven by improved operational efficiency and strategic capital raising activities during the quarter.

The Board of Directors approved the unaudited financial results on August 10, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subsequently published in Financial Express and Mumbai Lakshadeep under Regulation 47. The figures were reviewed by the Audit Committee and prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013.

Financial Performance Highlights

Transchem’s profitability expanded substantially in the opening quarter of FY26. Pre-tax profit stood at ₹435.21 lakh, compared to ₹135.10 lakh in Q1FY25. Basic earnings per share (EPS) rose to ₹2.79 from ₹0.81 in the prior year period. However, diluted EPS was lower at ₹0.57 due to the inclusion of recently issued warrants, whereas it remained at ₹0.81 in Q1FY25 when no such dilutive instruments were outstanding.

Capital Raise and Dilution Impact

During the quarter, Transchem issued 6,15,00,000 warrants on a preferential basis to non-promoter entities at an issue price of ₹75 per warrant. The company received an upfront consideration of 25% of the issue price, amounting to ₹18.75 per warrant, aggregating to ₹115.31 lakh. Each warrant carries the option to subscribe to one fully paid-up equity share with a face value of ₹10. These warrants can be exercised within 18 months from the date of allotment as per SEBI (Issue of Capital and Disclosure Requirements) Regulations.

What the Numbers Show

The divergence between basic EPS (₹2.79) and diluted EPS (₹0.57) highlights the immediate accounting impact of the warrant issuance on per-share metrics. While the core operational profit grew more than threefold, the potential conversion of these warrants into equity shares will significantly reduce earnings per share if exercised. Investors should note that the ₹115.31 lakh upfront receipt represents only a fraction of the potential capital inflow if all warrants are converted at the full ₹75 strike price over the next 18 months.